Washington, D.C. – On Thursday, December 12th, 2019, U.S. Representative Mark Green voted against the radically partisan prescription drug legislation introduced by House Democrats, H.R. 3.
H.R. 3 would ensure more Washington control, cripple the development of new cures and treatments, and has no chance of being signed into law by President Donald Trump.
Green said, “The President’s Council of Economic Advisers found that H.R. 3 could prevent 100 new cures from coming to market and lower Americans’ life expectancy by four months. That’s why I voted no on this partisan prescription drug plan.”
“We have a bipartisan solution on the table that can actually become law and unleash cures for millions of patients,” commented Green, who is an emergency room physician and cancer survivor. “The Lower Costs, More Cures Act has support from both sides of the aisle and will lower drug costs without harming innovation.”
“Let’s stop playing politics with Americans’ drug prices and pass the Lower Costs, More Cures Act, which does exactly what it says it will.”
The Lower Costs, More Cures Act is a bipartisan bill that will open the door for lifesaving cures, lower prescription drug costs, and increase transparency in the pharmaceutical market.